{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"

A Phase 2 Study to Evaluate the Efficacy and Safety of\nBelzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced\nPheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

","eudractNumber":"2020-005028-13","id":7072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":"NCT04924075","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-03-01T14:45:17+01:00","shortTitle":"Belzutifan/MK-6482 for the treatment of PPGL or pNET","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Beobachtung der Medizinischen Rehabilitation auf die Lebensqualität von Patientinnen und Patienten mit chronisch myeloischer Leukämie (CML)

Registriernummer DRKS00005385

","eudractNumber":null,"id":6558,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2013-12-23T08:57:59+01:00","shortTitle":"Beobachtung der Medizinischen Rehabilitation auf die Lebensqualität von Patientinnen und Patienten mit chronisch myeloischer Leukämie (CML)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht interventionelle Langzeitstudie (NIS) zum klinischen Einsatz von Biotest IVIGs in verschiedenen Indikationen. ","eudractNumber":null,"id":7451,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-09-01T11:16:22+02:00","shortTitle":"Biotest NIS-020 (IVIG)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"LiverageTM - A randomised, double-blind, placebo-controlled, multicentre, phase III trial evaluating long-term efficacy and safety off survodutide weekly injections in adult particpants with non-cirrhotic, non-alcoholic steatohepatitis - metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis","eudractNumber":"2024-513739-25-00","id":11353,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT06632444","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T14:22:17+02:00","shortTitle":"Boehringer Ingelheim 1404-0044","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"LiverageTM - A phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis-metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis","eudractNumber":"2024-513741-36-00","id":11352,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT06632457","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T09:50:33+02:00","shortTitle":"Boehringer Ingelheim 1404-0064","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Hirnmetastasen im Brustkrebs-Netzwerk Deutschland","eudractNumber":null,"id":7905,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-01-01T08:24:03+01:00","shortTitle":"Brain Metastases in Breast Cancer Network - BMBC (GBG 79)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive und Retrospektive Registerstudie der German Breast Group (GBG) Zur Diagnostik und Therapie des Mammakarzinoms in der Schwangerschaft mit jungen, nicht schwangeren Patientinnen (<40Jahre) als Vergleichskohorte","eudractNumber":null,"id":7904,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT00196833","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-01-01T08:20:45+01:00","shortTitle":"Breast Cancer in Pregnancy (BCP)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma

","eudractNumber":"2023-510178-15","id":10012,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-23T10:03:29+02:00","shortTitle":"CA073-1020 GOLSEEK-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"CAELUM Cardiac Amyloid Reaching for Extended Survival A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
","eudractNumber":"2019-004254-28","id":6946,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT04504825","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-26T11:02:10+02:00","shortTitle":"CAEL101-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
","eudractNumber":"2024-520154-38","id":10760,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-20T10:27:50+01:00","shortTitle":"CAMELOT - 2 75276617 AML3001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}